Regenxbio Inc (RGNX)
9.18
-0.45
(-4.67%)
USD |
NASDAQ |
Nov 21, 16:00
9.26
+0.08
(+0.87%)
Pre-Market: 08:23
Regenxbio Enterprise Value: 199.36M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 199.36M |
| November 20, 2024 | 221.66M |
| November 19, 2024 | 218.19M |
| November 18, 2024 | 247.42M |
| November 15, 2024 | 221.66M |
| November 14, 2024 | 296.47M |
| November 13, 2024 | 273.19M |
| November 12, 2024 | 264.27M |
| November 11, 2024 | 317.28M |
| November 08, 2024 | 297.46M |
| November 07, 2024 | 298.95M |
| November 06, 2024 | 211.75M |
| November 05, 2024 | 186.48M |
| November 04, 2024 | 178.56M |
| November 01, 2024 | 180.04M |
| October 31, 2024 | 170.13M |
| October 30, 2024 | 182.42M |
| October 29, 2024 | 193.32M |
| October 28, 2024 | 209.17M |
| October 25, 2024 | 207.68M |
| October 24, 2024 | 219.08M |
| October 23, 2024 | 227.00M |
| October 22, 2024 | 219.57M |
| October 21, 2024 | 258.21M |
| October 18, 2024 | 294.37M |
| Date | Value |
|---|---|
| October 17, 2024 | 269.60M |
| October 16, 2024 | 277.03M |
| October 15, 2024 | 254.74M |
| October 14, 2024 | 249.79M |
| October 11, 2024 | 234.43M |
| October 10, 2024 | 204.71M |
| October 09, 2024 | 202.23M |
| October 08, 2024 | 218.08M |
| October 07, 2024 | 216.10M |
| October 04, 2024 | 226.01M |
| October 03, 2024 | 207.68M |
| October 02, 2024 | 235.92M |
| October 01, 2024 | 250.28M |
| September 30, 2024 | 264.15M |
| September 27, 2024 | 243.41M |
| September 26, 2024 | 237.48M |
| September 25, 2024 | 244.90M |
| September 24, 2024 | 263.68M |
| September 23, 2024 | 286.41M |
| September 20, 2024 | 287.40M |
| September 19, 2024 | 327.43M |
| September 18, 2024 | 328.92M |
| September 17, 2024 | 349.67M |
| September 16, 2024 | 339.29M |
| September 13, 2024 | 344.24M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
170.13M
Minimum
Oct 31 2024
1.709B
Maximum
Feb 13 2020
793.11M
Average
756.80M
Median
Mar 07 2024
Enterprise Value Benchmarks
| Catalyst Pharmaceuticals Inc | 2.077B |
| EyePoint Pharmaceuticals Inc | 316.10M |
| Cassava Sciences Inc | 1.399B |
| Vertex Pharmaceuticals Inc | 109.46B |
| Sarepta Therapeutics Inc | 10.58B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -59.60M |
| Revenue (Quarterly) | 24.20M |
| Total Expenses (Quarterly) | 86.28M |
| EPS Diluted (Quarterly) | -1.17 |
| Gross Profit Margin (Quarterly) | 48.81% |
| Profit Margin (Quarterly) | -246.3% |
| Earnings Yield | -54.68% |
| Normalized Earnings Yield | -56.81 |